 phase II study days cisplatin recombinant interferon advanced non-small cell lung cancer Preclinical data studies human lung cancer cytotoxic effects cisplatin alpha-interferon observations authors Phase II trial advanced non-small cell lung cancer NSCLC Cisplatin cycle divided day day schedule day interferon dose units times week minimum months Between January September patients response toxicity system Mountain patients Stage IV disease Stage IIIB disease Stage IIIA disease Expression neuron-specific enolase NSE possible relationship treatment response response rate confidence interval CI responders positivity NSE positive average cycles mean dose intensity dose cisplatin dose interferon standard scale interferon toxicity Hematologic renal systemic side effects significant advanced NSCLC addition interferon cisplatin-induced response rate studies real value chemotherapy response tumors positive immunoreactivity neural markers NSE